Item 8.01. Other Events.

On June 8, 2009, Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced that its collaborator, Ono Pharmaceutical Co., Ltd., Osaka, Japan (OSE-TYO: 4528), has begun clinical testing in Japan of RELISTOR® (methylnaltrexone bromide) subcutaneous injection pursuant to the License Agreement between Progenics and Ono, under which Ono has exclusive rights to subcutaneous RELISTOR in Japan and where it is pursuing plans to develop and commercialize the drug, designated ONO-3849, for the treatment of opioid-induced constipation.

On the same date, Progenics announced the discontinuation of development for PRO 206, a pre-clinical compound for the treatment of hepatitis C virus (HCV) infection, in line with its ongoing initiative to allocate resources to the most important programs in order to increase operating efficiencies, and that it will instead focus on its second-generation HCV-entry inhibitor portfolio, anticipating selection of a new development candidate in 2010.

Copies of each press release are attached hereto as Exhibits 99.1 and 99.2, respectively, and the information contained therein is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1 Relistor Press Release dated June 8, 2009.
99.2 PRO 206 Press Release dated June 8, 2009.

---